Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-THINc ESRD: Fesomersen for Thrombosis Prevention in Hemodialysis
NCT04534114Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 15
01
Overview
A Phase 2 trial of fesomersen in thromboembolism, sponsored by Bayer. Started Sep 2020; status: completed.
02
Drugs
fesomersen
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04534114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534114.